The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis

Alveolar rhabdomyosarcoma (aRMS) is a childhood soft tissue sarcoma driven by the signature (P3F) fusion gene. Five-year survival for aRMS is

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2018-06, Vol.24 (11), p.2616-2630
Main Authors: Deel, Michael D, Slemmons, Katherine K, Hinson, Ashley R, Genadry, Katia C, Burgess, Breanne A, Crose, Lisa E S, Kuprasertkul, Nina, Oristian, Kristianne M, Bentley, Rex C, Linardic, Corinne M
Format: Article
Language:English
Subjects:
Alveoli
Animals
Apoptosis
Apoptosis - genetics
Carcinoma
Cell cycle
Cell Cycle - genetics
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Neoplastic - genetics
Cell Transformation, Neoplastic - metabolism
Children
Disease Models, Animal
DNA microarrays
Experimental design
Forkhead Box Protein O1 - genetics
Forkhead Box Protein O1 - metabolism
FOXO1 protein
Fusion protein
Gene Expression Regulation, Neoplastic
Heterografts
Humans
In vivo methods and tests
Mice
Myoblasts - metabolism
Pax3 protein
PAX3 Transcription Factor - genetics
PAX3 Transcription Factor - metabolism
Pharmacology
Phenotypes
Rhabdomyosarcoma
Rhabdomyosarcoma, Alveolar - genetics
Rhabdomyosarcoma, Alveolar - metabolism
RNA-mediated interference
Sarcoma
Soft tissue sarcoma
Trans-Activators
Transcription
Transcription Factors - genetics
Transcription Factors - metabolism
Transcriptional Activation
Tumorigenesis
Tumors
Vincristine
Xenografts
Xenotransplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alveolar rhabdomyosarcoma (aRMS) is a childhood soft tissue sarcoma driven by the signature (P3F) fusion gene. Five-year survival for aRMS is
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-17-1207